Day: September 23, 2022

Capital Power and Manulife Investment Management complete acquisition of Midland Cogeneration facility

Written by Customer Service on September 23, 2022. Posted in Mergers And Acquisitions.

EDMONTON, Alberta, Sept. 23, 2022 (GLOBE NEWSWIRE) — Capital Power Corporation (TSX: CPX) (“Capital Power”) and Manulife Investment Management, on behalf of the Manulife Infrastructure Fund II and its affiliates, announced today that they have successfully completed the acquisition of a 100% interest in MCV Holding Company, which owns Midland Cogeneration Venture (“Midland Cogen”), a 1,633-megawatt natural gas combined-cycle cogeneration facility. The acquisition was previously announced on July 12, 2022. Midland Cogen was acquired from OMERS Infrastructure Management Inc. and its co-investors for US$894 million, subject to working capital and other closing adjustments, and includes the assumption of US$521 million of project level debt. Under the 50/50 joint venture with Manulife Investment Management, Capital Power and its joint...

Israeli Technology Company BYND Cannasoft Closes Acquisition of Zigi Carmel Investments Ltd. Valued at US $28 Million

Written by Customer Service on September 23, 2022. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced today that, further to its news release of September 19, 2022, it has completed the purchase of all of the issued and outstanding shares of Zigi Carmel Initiatives & Investments Ltd. (“ZC”) from Carmel Zigdon. Under the terms of the share purchase agreement, the Company issued 7,920,000 common shares to the vendor. These shares are subject to a hold period and may not be traded in Canada before January 23, 2023. The Company also reports that Carmel has been appointed as a director of BYND. Carmel invented the concept for the EZ-G device back in 2021 and since then has developed it for commercialization. He currently manages the online shopping site ZCRAIV, an online clothes...

Nordic American Tankers Ltd (NYSE: NAT) – Solid rates and earnings

Written by Customer Service on September 23, 2022. Posted in Public Companies.

Friday, September 23, 2022 Dear Shareholders and Investors, This is to reconfirm that the business of NAT(rates, earnings) is solid and prospects are good. For contacts, please see at the end of this communication. Sincerely, Herbjorn HanssonFounder, Chairman & CEONordic American Tankers Limited CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other...

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval

Written by Customer Service on September 23, 2022. Posted in Public Companies.

FREEMONT, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced enrollment progress in the Phase II Part 2 clinical study of the Company’s ADHD medicine, ABV-1505, currently being conducted at five prestigious medical centers in Taiwan. The Part 2 study is a randomized, double-blind, placebo-controlled study, titled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part 2” and is expected to eventually enroll approximately 100 patients in Taiwan and the United States. Since results of the first subject treated in Taiwan were reported on May 10, 2022, 30 subjects...

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

Written by Customer Service on September 23, 2022. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time. The webcast will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor...

SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants

Written by Customer Service on September 23, 2022. Posted in Public Companies.

SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (“SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today that the Company will present new data on its fully-human polyclonal antibody platform’s ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, 2022. SAB will conduct an oral presentation, titled “Efficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza...

Medigus Announces Record 2022 First Half Financial Results

Written by Customer Service on September 23, 2022. Posted in Earnings Releases And Operating Results.

Record Revenues of $34.95 million, up over 1,300% Y-o-Y TEL AVIV, Israel, Sept. 23, 2022 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS) (“Medigus”), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today reported financial results for the six months ended June 30, 2022. Key HighlightsGenerated record revenues of $34.95 million in the first half of 2022, compared to $2.39 million revenues in the first half of 2021 Gross profit reached a record $6.19 million in the first half of 2022, up from a gross profit of $0.6 million in the first half of 2021 Cash and cash equivalents as of June 30, 2022 were $22.1 million Shareholders’ equity improved to $53.19 million as of June 30, 2022, up from $51.43 million at December 31, 2021“Our record first...

Daseke Appoints Aaron Coley as Executive Vice President, Chief Financial Officer and Reaffirms Fiscal 2022 Outlook

Written by Customer Service on September 23, 2022. Posted in Public Companies.

Company reaffirms full-year 2022 revenue growth outlook of 12% – 15% and Adjusted EBITDA growth outlook of 5%-10% year-over-year, supported by solid execution and demand and rate resilience in industrial-facing freight markets ADDISON, Texas, Sept. 23, 2022 (GLOBE NEWSWIRE) — Daseke, Inc. (NASDAQ: DSKE) (“Daseke” or the “Company”), the premier North American transportation solutions specialist dedicated to servicing challenging industrial end-markets, announced today that it has named Aaron Coley as the Company’s new Executive Vice President, Chief Financial Officer (“CFO”), effective October 28th of this year. In this role, Mr. Coley will be responsible for managing all treasury, accounting, tax, investor relations, financial planning and analysis, and capital market activities, and will be charged with managing the Company’s...

Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)

Written by Customer Service on September 23, 2022. Posted in Public Companies.

Understanding Hunger & Bardet-Biedl Syndrome (BBS): Gabe’s Story Developed in collaboration with the Bardet-Biedl Syndrome (BBS) Foundation— Book developed in collaboration with the Bardet-Biedl Syndrome Foundation — — BBS Global Day on Sept. 24 coordinated by BBS International — BOSTON, Sept. 23, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the publication of a children’s book developed in collaboration with the Bardet-Biedl Syndrome (BBS) Foundation. The publication announcement of the book, titled, “Understanding Hunger & Bardet-Biedl Syndrome...

Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit

Written by Customer Service on September 23, 2022. Posted in Public Companies.

SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022. Nautilus co-founder and CEO Sujal Patel is scheduled to participate in the following two executive panel discussions:Proteomics “Everything You Wanted to Know, But Were Afraid to Ask” at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time CEOs from Spatial Biology/Proteomics at 1:00 p.m. Eastern Time / 10 a.m. Pacific TimeInterested parties may contact kristen.patrick@capitalone.com to register to attend the virtual event. About Nautilus Biotechnology, Inc.With...

Day: September 23, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals